Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

BPC-157 Compounding Pharmacy: How to Read a Certificate of Analysis

By
Published Updated Last reviewed
9 linked public sourcesEditorial, sourcing, and corrections policy

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

Key numbers

  • 15-amino-acidNumber of amino acids in the peptide chain, per FDA's description of the peptideSource: fda.gov, as cited 2026-11-07
  • 3 adverse-event reportsAdverse-event reports FDA found for the peptide, all injectable; cause could not be determinedSource: fda.gov, as cited 2026-11-07
  • 30 patientsTotal patients across human studies of the peptide in a 2026 systematic reviewSource: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07

At a glance

  • What a COA is / A batch testing record, not an approval
  • BPC-157 approval status / Not FDA-approved; no FDA-approved drug contains it [3]
  • Draft HHS policy / Valid COA meeting a peptide testing standard, BPC-157 acetate only [1]
  • Policy status / Draft, nonbinding, not an approval or listing [2][1]
  • FDA list status / Not on FDA's list for state-licensed pharmacies or outsourcing facilities [4][5]
  • Human safety data / FDA called the clinical safety information insufficient [3]

What a BPC-157 COA covers

A COA reports tests on one lot. It does not make BPC-157 approved, legal to compound, effective, or safe. BPC-157 is a 15-amino-acid synthetic peptide with no FDA-approved drug product and no US Pharmacopeia or National Formulary monograph [3]. FDA treats the free base and the acetate salt as two different bulk substances [3]. The draft policy covers acetate only [1].

The COA condition in the draft HHS policy

HHS announced the draft on October 28, 2026, with Federal Register publication scheduled for October 30 and two weeks of comment [2]. It says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding with listed peptides if conditions are met [2]. For BPC-157, the conditions include acetate only; subcutaneous, intramuscular, oral, or topical forms; a single active ingredient; a bulk substance from an FDA-registered manufacturer with a valid COA meeting a peptide testing standard; a patient-specific prescription; and MedWatch reporting of serious adverse events and quality problems [1]. Nasal, rectal, and intravenous forms are not listed, and the policy names state-licensed pharmacies, federal facilities, and licensed physicians, not outsourcing facilities [1]. HHS may revisit the policy [2][1].

What to check on the COA

  • Form: acetate or free base. The draft policy covers acetate [3][1].
  • Ingredient count: the policy requires a single active ingredient, so a BPC-157 and TB-500 blend does not meet that condition [1].
  • Route: the policy lists subcutaneous, intramuscular, oral, and topical forms [1].
  • Bulk manufacturer: the policy requires the bulk substance to come from an FDA-registered manufacturer, with a valid COA meeting a peptide testing standard [1].

FDA has said compounded BPC-157 may pose an immunogenicity risk for certain routes and may have peptide-related impurities and problems characterizing the active ingredient [6].

What people on Reddit report

Reddit posts and replies from one peptide thread about two lab reports for the same batch, where people weigh endotoxin and purity results differently.

hinglecringleberry0 · bpc_157

The numbers vary from and are worse than the Janoshik testing on eternal peptides website for the same batch.

Poster reports that two labs gave different results for the same batch and asks whether the endotoxin and purity results are a concern.

Read the source discussion

The_Last_Boyscout · bpc_157

They hit the score hard for under/over fill which to me is not as big a deal as purity. Personally, I would like to see 99% plus but its not horrible.

Commenter says fill problems matter less than purity, and that endotoxin results are probably fine.

Read the source discussion

Aggravating-Grade297 · bpc_157

Endotoxins are only 25% of limits. So ok there. Purity could be higher. I'd probably filter it due to the low purity. Then use it.

Commenter says endotoxins were well within limits but would filter a vial with low purity before using it.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

What the COA cannot tell you

A COA is not a safety study. FDA found 3 adverse-event reports, all injectable, and could not tell whether BPC-157 caused them; it concluded there is insufficient clinical safety information to characterize BPC-157 [3]. A 2026 systematic review found only 3 human studies with 30 patients total, all of poor methodological quality and very low certainty of evidence [7].

Dr Ashley Froese on why a certificate of analysis cannot guarantee purity

Dr Froese argues that a certificate of analysis is not proof of what is in a peptide vial. She describes the COA as a PDF shown beside a product, with peaks and valleys meant to suggest high purity, but she warns that COAs can and have been faked. In her view the peptide market is largely unregulated, purity varies widely, and plenty of companies fake or fudge these certificates. She does not encourage buying peptides from random sources, and her point is that a PDF on a website does not guarantee purity.

Who is speaking?

Dr. Ashley Froese. Primary care doctor running a direct primary care clinic, as she describes herself in the video Background

Episode notes and full video

Frequently asked questions

Does a BPC-157 COA make the product legal?
No. BPC-157 is not FDA-approved and is not on FDA's list for state-licensed pharmacies or outsourcing facilities. The draft HHS policy says it does not intend enforcement against certain state-licensed pharmacies and physicians if conditions, including a valid COA, are met, but it is a nonbinding draft, not an approval [3][4][5][2][1].
What COA condition does the draft HHS policy set for BPC-157?
For BPC-157 acetate, the bulk substance must come from an FDA-registered manufacturer with a valid COA meeting a peptide testing standard. The product must be a single active ingredient in a listed route, with a patient-specific prescription and the label 'This is a compounded drug product. Not for resale.' [1].
Is 98 percent HPLC purity a BPC-157 standard?
The draft policy states its COA condition as a valid COA meeting a peptide testing standard [1]. There is no US Pharmacopeia or National Formulary monograph for BPC-157 [3]. FDA's stated concerns include peptide-related impurities and characterization of the active ingredient [6].
Does the draft policy cover nasal or intravenous BPC-157?
No. The draft policy lists subcutaneous, intramuscular, oral, and topical forms. Nasal, rectal, and intravenous forms are not listed [1].

References

  1. Official web page. Official web page
  2. Official web page. Official web page
  3. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  4. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  5. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  6. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
  7. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety
  8. Reddit participants. Lab Test Results for Eternal Peptides BPC-157. Thoughts? (r/bpc_157). Accessed 2026-11-11.
  9. This Is Not Covered - Dr. Ashley Froese. Before You Start Peptides: A Doctor Answers Your Biggest Questions. Accessed 2026-11-11.
Evidence overview for BPC-157 Compounding Pharmacy: How to Read a Certificate of Analysis